rash on the injection site; redness on the injection site; swelling on injection site; muscle soreness for 2 days; This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MYALGIA (muscle soreness for 2 days), VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical history information was reported.     On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced MYALGIA (muscle soreness for 2 days). On 20-Jan-2021, the patient experienced VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site). On 15-Jan-2021, MYALGIA (muscle soreness for 2 days) had resolved. At the time of the report, VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient stated she had to seek medical attention. Patient was started on Doxycycline 100 mg Twice a day for 7 days.   Concomitant medications were not reported. This case was received via an unknown source (no reference has been entered for a health authority or license partner) on 22-Jan-2021 and was forwarded to Moderna on 23-Jan-2021.    This spontaneous case was reported by a consumer (subsequently medically confirmed) and describes the occurrence of MYALGIA (muscle soreness for 2 days), VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site) in a 42-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 025L20A) for COVID-19 vaccination.     No Medical history information was reported.     On 13-Jan-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) 1 dosage form. On 13-Jan-2021, the patient experienced MYALGIA (muscle soreness for 2 days). On 20-Jan-2021, the patient experienced VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site). On 15-Jan-2021, MYALGIA (muscle soreness for 2 days) had resolved. At the time of the report, VACCINATION SITE RASH (rash on the injection site), VACCINATION SITE ERYTHEMA (redness on the injection site) and VACCINATION SITE SWELLING (swelling on injection site) outcome was unknown. Not Provided      The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Intramuscular) was unknown.       Patient stated she had to seek medical attention. Patient was started on Doxycycline 100 mg Twice a day for 7 days.   Concomitant medications were not reported.